Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
Authors:
Top Cited Papers
- 1 January 2021
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (1) , e22-e33
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled AnalysisCirculation, 2014
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in childrenJournal of Thrombosis and Haemostasis, 2011
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007Pediatrics, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort studyThe Lancet Neurology, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- Maturation and growth of renal function: Dosing renally cleared drugs in childrenAAPS PharmSci, 2000
- Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding studyThe Journal of Pediatrics, 1996